SynthesisBMC medicine2026
Discriminative performance of externally validated dementia risk prediction models: a systematic review and meta-analysis.
Synthesis in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characteristics of publicly available digital dementia risk screening tools: A scoping review.Journal of Alzheimer's disease reportsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundData on the external validation of current dementia risk prediction models has not yet been systematically synthesised. This systematic review and meta-analysis collated results from three previous reviews to evaluate the predictive discriminative performance of dementia risk models when validated in population-based settings.
methodsEmbase (via Ovid), Medline (via Ovid), Scopus, and Web of Science were searched from inception to June 2022 with an updated search conducted up to November 2024. Included studies (1) had a population-based cohort design; (2) assessed incident late-life (i.e. ≥ 60 years) dementia; and (3) reported predictive performance of at least one dementia risk prediction model in an independent validation sample. Information on study characteristics, dementia outcomes, prediction models (including whether they were fully validated [all original variables available and mapped] or partially validated [one or more variables missing or substituted]), and their discriminative performance were extracted in duplicate. Discrimination, quantified by the area under the receiver operating characteristic curve (AUC) or c-statistic, was pooled across studies using a random-effects model. Models were stratified by validation type: fully versus partially validated.
resultsThirty-six studies were included. Seventeen studies undertook full validation (14 unique prediction models) and were included in the meta-analysis. Predictor count ranged from one to 57. For all-cause dementia, RADaR showed the highest performance (c-statistic = 0.83, 95%CI: 0.80-0.86; n = 2 validations), followed by eRADAR (c-statistic = 0.81, 95%CI: 0.75-0.85; n = 2 validations). The BDSI model had the most validations (all-cause dementia c-statistic = 0.72, 95%CI: 0.69-0.75; n = 13 validations; and Alzheimer's disease c-statistic = 0.74, 95%CI: 0.61-0.87; n = 2 validations) and performed similarly across high- and middle-income counties. Most validations (76%) were conducted in high-income countries, with 24% in upper-middle income countries. Considerable variation in heterogeneity was observed across models (I
conclusionsSeveral dementia risk prediction models demonstrate moderate to high external validity. The BDSI model, tested across multiple settings and dementia outcomes, showed promising generalisability. However, the limited number of fully validated models and scarcity of studies in low-income country settings highlight the need for further research on feasibility, resource requirements, and cost-effectiveness before clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.